CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company's founder, Chief Medical Officer, and President of Research & Development (R&D), will transition to the role of Senior Scientific and Medical Advisor. Dr. Taub will continue to serve on Madrigal's Board of Directors. Succeeding ...

Company Overview - Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) [5] - The company's medication, Rezdiffra (resmetirom), is the first and only FDA-approved treatment for MASH with moderate to advanced fibrosis [6] Leadership Transition - Rebecca Taub, M.D., the founder and Chief Medical Officer, will transition to Senior Scientific and Medical Advisor while continuing on the Board of Directors [1] - David Soergel, M.D., has been appointed as the new Executive Vice President and Chief Medical Officer, effective April 21, 2025 [1] Achievements and Future Plans - Under Dr. Taub's leadership, Madrigal achieved the milestone of developing Rezdiffra, the first FDA-approved medicine for MASH, providing hope to patients [2][3] - Dr. Soergel brings over 20 years of experience in drug development for metabolic and cardiovascular diseases, which aligns with the company's goal to expand its pipeline beyond Rezdiffra [3][4] Company Growth - Madrigal has grown from a small team of fewer than 10 R&D professionals to a commercial-stage biopharma company with over 500 employees across the U.S. and Europe [3]

It has been about a month since the last earnings report for Madrigal (MDGL) . Shares have added about 0.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Madrigal due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns o ...

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn (“Jackie”) Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, s ...

Madrigal Pharmaceuticals (MDGL) reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus Estimate of a loss of $4.12. In the year-ago quarter, the company had incurred a loss of $5.68 per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.During the quarter, the company generated total revenues of $103.3 million entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom), which was approved la ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL ) announced its Q4 and full-year 2024 earnings earlier today, and the market's initial response has been positive, with shares ...

Shares of Madrigal Pharmaceuticals (MDGL 17.62%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and full-year 2024 results before the market opened.Madrigal reported fourth-quarter revenue of $103.3 million, all of which stemmed from sales of Rezdiffra, the first drug approved for treating metabolic dysfunction-associated steatohepatitis (MASH). The company posted a net loss in Q4 of $59.4 million, or $2.71 ...

Fourth-Quarter and Full-Year 2024 Financial Results Feb. 26, 2025 NASDAQ: MDGL Forward-Looking Statements This presentation includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal's beliefs and assumptions and on information currently available to it but are subject to factors beyond its control. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectation ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - CEO, President & Director Mardi Dier - CFO & Senior VP Michael Charlton - Head of Clinical Development Conference Call Participants Thomas Smith - Leerink Partners Andrea Newkirk - Goldman Sachs Yasmeen Rahimi - Piper Sandler Ellie Merle - UBS Amy Li - Jefferies Liisa Bayko - Evercore ISI David Lebowitz - Citi Andy Chen ...

Madrigal (MDGL) came out with a quarterly loss of $2.71 per share versus the Zacks Consensus Estimate of a loss of $4.12. This compares to loss of $5.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 34.22%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $6.94 per share when it actually produced a loss of $4.92, delivering a surprise of 29.11%.Over the last four quarters, the company h ...